Does the media favor PRCT or RCEL?

In the previous week, PROCEPT BioRobotics had 45 more articles in the media than Avita Medical. MarketBeat recorded 46 mentions for PROCEPT BioRobotics and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.71 beat PROCEPT BioRobotics' score of 0.23 indicating that Avita Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 7 Very Positive mention(s) 5 Positive mention(s) 33 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avita Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STAA or RCEL?

In the previous week, STAAR Surgical had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for STAAR Surgical and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.71 beat STAAR Surgical's score of 0.15 indicating that Avita Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avita Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, BVS or RCEL?

Bioventus has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.08 $22.73M $0.77 18.27 Avita Medical $71.61M 4.81 -$48.59M -$1.44 N/A

Does the media favor BVS or RCEL?

In the previous week, Bioventus and Bioventus both had 1 articles in the media. Bioventus' average media sentiment score of 1.02 beat Avita Medical's score of 0.71 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IRMD or RCEL?

iRadimed has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 12.74 $22.48M $1.79 46.62 Avita Medical $71.61M 4.81 -$48.59M -$1.44 N/A

Is IRMD or RCEL more profitable?

iRadimed has a net margin of 26.70% compared to Avita Medical's net margin of -56.96%. iRadimed's return on equity of 23.45% beat Avita Medical's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Avita Medical -56.96% N/A -78.53%

Does the media favor IRMD or RCEL?

In the previous week, iRadimed had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for iRadimed and 1 mentions for Avita Medical. iRadimed's average media sentiment score of 1.47 beat Avita Medical's score of 0.71 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RCEL or NNNN?

Avita Medical presently has a consensus target price of $11.40, indicating a potential upside of 1.79%. Given Avita Medical's stronger consensus rating and higher probable upside, analysts clearly believe Avita Medical is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avita Medical 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, RCEL or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Avita Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avita Medical $71.61M 4.81 -$48.59M -$1.44 N/A Anbio Biotechnology $8.65M 108.79 $6.40M N/A N/A

Is RCEL or NNNN more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to Avita Medical's net margin of -56.96%. Company Net Margins Return on Equity Return on Assets Avita Medical -56.96% N/A -78.53% Anbio Biotechnology N/A N/A N/A

Avita Medical (RCEL) Competitors

$11.20 +0.26 (+2.38%)

As of 09/4/2026 04:00 PM Eastern

Compare

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

Should you buy Avita Medical stock or one of its competitors? Avita Medical's main competitors and comparable companies include PROCEPT BioRobotics (PRCT), STAAR Surgical (STAA), Bioventus (BVS), iRadimed (IRMD), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Avita Medical compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

PROCEPT BioRobotics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 2.2% of Avita Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avita Medical has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$337.34M	3.86	-$95.57M	-$1.94	N/A
Avita Medical	$71.61M	4.81	-$48.59M	-$1.44	N/A

In the previous week, PROCEPT BioRobotics had 45 more articles in the media than Avita Medical. MarketBeat recorded 46 mentions for PROCEPT BioRobotics and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.71 beat PROCEPT BioRobotics' score of 0.23 indicating that Avita Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	7 Very Positive mention(s)	5 Positive mention(s)	33 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avita Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PROCEPT BioRobotics currently has a consensus target price of $25.09, indicating a potential upside of 10.24%. Avita Medical has a consensus target price of $11.40, indicating a potential upside of 1.79%. Given PROCEPT BioRobotics' higher possible upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

PROCEPT BioRobotics has a net margin of -32.53% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Avita Medical	-56.96%	N/A	-78.53%

Summary

Avita Medical beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does Avita Medical compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Avita Medical has lower revenue, but higher earnings than STAAR Surgical. Avita Medical is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	4.91	-$80.45M	$0.07	335.29
Avita Medical	$71.61M	4.81	-$48.59M	-$1.44	N/A

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, STAAR Surgical had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for STAAR Surgical and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.71 beat STAAR Surgical's score of 0.15 indicating that Avita Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avita Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STAAR Surgical currently has a consensus target price of $28.40, suggesting a potential upside of 21.01%. Avita Medical has a consensus target price of $11.40, suggesting a potential upside of 1.79%. Given STAAR Surgical's higher probable upside, research analysts plainly believe STAAR Surgical is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

STAAR Surgical has a net margin of 1.13% compared to Avita Medical's net margin of -56.96%. STAAR Surgical's return on equity of 9.05% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	1.13%	9.05%	6.99%
Avita Medical	-56.96%	N/A	-78.53%

STAAR Surgical has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Summary

STAAR Surgical beats Avita Medical on 11 of the 16 factors compared between the two stocks.

How does Avita Medical compare to Bioventus?

Bioventus (NASDAQ:BVS) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bioventus and Bioventus both had 1 articles in the media. Bioventus' average media sentiment score of 1.02 beat Avita Medical's score of 0.71 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus currently has a consensus price target of $16.80, indicating a potential upside of 19.40%. Avita Medical has a consensus price target of $11.40, indicating a potential upside of 1.79%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts plainly believe Bioventus is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Bioventus has a net margin of 9.36% compared to Avita Medical's net margin of -56.96%. Bioventus' return on equity of 28.08% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Avita Medical	-56.96%	N/A	-78.53%

Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

Bioventus has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.08	$22.73M	$0.77	18.27
Avita Medical	$71.61M	4.81	-$48.59M	-$1.44	N/A

Summary

Bioventus beats Avita Medical on 12 of the 14 factors compared between the two stocks.

How does Avita Medical compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

iRadimed has a net margin of 26.70% compared to Avita Medical's net margin of -56.96%. iRadimed's return on equity of 23.45% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Avita Medical	-56.96%	N/A	-78.53%

92.3% of iRadimed shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

iRadimed currently has a consensus target price of $120.00, suggesting a potential upside of 43.80%. Avita Medical has a consensus target price of $11.40, suggesting a potential upside of 1.79%. Given iRadimed's stronger consensus rating and higher possible upside, analysts clearly believe iRadimed is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

iRadimed has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.74	$22.48M	$1.79	46.62
Avita Medical	$71.61M	4.81	-$48.59M	-$1.44	N/A

In the previous week, iRadimed had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for iRadimed and 1 mentions for Avita Medical. iRadimed's average media sentiment score of 1.47 beat Avita Medical's score of 0.71 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Summary

iRadimed beats Avita Medical on 15 of the 17 factors compared between the two stocks.

How does Avita Medical compare to Anbio Biotechnology?

Avita Medical (NASDAQ:RCEL) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Anbio Biotechnology has a net margin of 0.00% compared to Avita Medical's net margin of -56.96%.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Anbio Biotechnology	N/A	N/A	N/A

27.7% of Avita Medical shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Avita Medical presently has a consensus target price of $11.40, indicating a potential upside of 1.79%. Given Avita Medical's stronger consensus rating and higher probable upside, analysts clearly believe Avita Medical is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Avita Medical had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 1 mentions for Avita Medical and 0 mentions for Anbio Biotechnology. Avita Medical's average media sentiment score of 0.71 beat Anbio Biotechnology's score of 0.00 indicating that Avita Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Avita Medical	Positive
Anbio Biotechnology	Neutral

Anbio Biotechnology has lower revenue, but higher earnings than Avita Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	4.81	-$48.59M	-$1.44	N/A
Anbio Biotechnology	$8.65M	108.79	$6.40M	N/A	N/A

Avita Medical has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.17, meaning that its share price is 417% more volatile than the broader market.

Summary

Avita Medical beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

Get Avita Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCEL vs. The Competition

Export

Metric	Avita Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$344.70M	$5.76B	$7.25B	$12.92B
Dividend Yield	N/A	1.76%	2.53%	9.14%
P/E Ratio	-7.78	25.82	273.54	25.43
Price / Sales	4.81	73.69	628.85	97.30
Price / Cash	N/A	32.98	77.08	52.44
Price / Book	-12.44	6.06	12.85	6.17
Net Income	-$48.59M	$150.92M	$3.49B	$350.08M
7 Day Performance	8.21%	-1.22%	1.04%	-0.14%
1 Month Performance	135.79%	1.96%	5.52%	1.02%
1 Year Performance	162.91%	10.79%	24.39%	14.51%

Avita Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCEL Avita Medical	1.957 of 5 stars	$11.20 +2.4%	$11.40 +1.8%	+162.9%	$344.70M	$71.61M	N/A	130
PRCT PROCEPT BioRobotics	2.5866 of 5 stars	$20.48 -3.4%	$28.00 +36.7%	-44.1%	$1.17B	$308.05M	N/A	430	Trending News
STAA STAAR Surgical	3.3749 of 5 stars	$23.02 +1.9%	$28.40 +23.4%	-16.0%	$1.15B	$239.44M	328.70	1,211	Analyst Downgrade
BVS Bioventus	4.5579 of 5 stars	$13.55 -0.7%	$16.80 +24.0%	+95.7%	$1.14B	$581.85M	17.61	1,200	Positive News
IRMD iRadimed	2.7063 of 5 stars	$87.42 +1.2%	$120.00 +37.3%	+15.9%	$1.12B	$83.81M	48.83	110	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCEL) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avita Medical (RCEL) Competitors

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

How does Avita Medical compare to PROCEPT BioRobotics?

Summary

How does Avita Medical compare to STAAR Surgical?

Summary

How does Avita Medical compare to Bioventus?

Summary

How does Avita Medical compare to iRadimed?

Summary

How does Avita Medical compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCEL vs. The Competition

Avita Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avita Medical (RCEL) Competitors

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

How does Avita Medical compare to PROCEPT BioRobotics?

Which has more risk & volatility, PRCT or RCEL?

Do insiders & institutionals believe in PRCT or RCEL?

Which has stronger earnings and valuation, PRCT or RCEL?

Does the media favor PRCT or RCEL?

Do analysts rate PRCT or RCEL?

Is PRCT or RCEL more profitable?

Summary

How does Avita Medical compare to STAAR Surgical?

Which has preferable earnings and valuation, STAA or RCEL?

Do insiders and institutionals have more ownership in STAA or RCEL?

Does the media favor STAA or RCEL?

Do analysts prefer STAA or RCEL?

Is STAA or RCEL more profitable?

Which has more volatility and risk, STAA or RCEL?

Summary

How does Avita Medical compare to Bioventus?

Do insiders & institutionals believe in BVS or RCEL?

Does the media favor BVS or RCEL?

Do analysts recommend BVS or RCEL?

Is BVS or RCEL more profitable?

Which has more volatility and risk, BVS or RCEL?

Which has stronger valuation and earnings, BVS or RCEL?

Summary

How does Avita Medical compare to iRadimed?

Is IRMD or RCEL more profitable?

Do institutionals & insiders hold more shares of IRMD or RCEL?

Do analysts rate IRMD or RCEL?

Which has better valuation and earnings, IRMD or RCEL?

Does the media favor IRMD or RCEL?

Which has more risk & volatility, IRMD or RCEL?

Summary

How does Avita Medical compare to Anbio Biotechnology?

Is RCEL or NNNN more profitable?

Do institutionals and insiders believe in RCEL or NNNN?

Do analysts prefer RCEL or NNNN?

Does the media refer more to RCEL or NNNN?

Which has higher earnings and valuation, RCEL or NNNN?

Which has more volatility and risk, RCEL or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCEL vs. The Competition

Avita Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools